Intestinal Research.2013;11(4):330-331. doi:10.5217/ir.2013.11.4.330
No abstract available.
Intestinal Research
to Present ISSN: 1598-9100
Sort by
DISPLAY OPTIONS
Format:
Per page:
The Real State of Colonoscopy Quality of Non-tertiary Hospitals in Korea.
Intestinal Research.2013;11(4):327-329. doi:10.5217/ir.2013.11.4.327
Intestinal Research.2013;11(4):325-326. doi:10.5217/ir.2013.11.4.325
No abstract available.
Antibodies, Monoclonal, Humanized ; Colitis, Ulcerative* ; Crohn Disease* ; Ulcer*
Antibodies, Monoclonal, Humanized ; Colitis, Ulcerative* ; Crohn Disease* ; Ulcer*
Intestinal Research.2014;12(3):260-261. doi:10.5217/ir.2014.12.3.260
No abstract available.
Intestinal Research.2014;12(3):258-259. doi:10.5217/ir.2014.12.3.258
A Patient with Hematochezia and Intestinal Obstruction.
Intestinal Research.2014;12(3):256-257. doi:10.5217/ir.2014.12.3.256
Intestinal Research.2014;12(3):251-255. doi:10.5217/ir.2014.12.3.251
Gastrocolocutaneous fistula is a rare complication of the percutaneous endoscopic gastrostomy (PEG) procedure. Typical symptoms usually occur in the first few months. We recently encountered 2 patients with 8- and 33-month asymptomatic periods. A 74-year-old man presented with watery diarrhea for 1 month. He had undergone PEG 9 months earlier. During workup, an upper endoscopy and abdominal CT scan revealed the migration of the feeding tube into the transverse colon. He was discharged with a nasogastric tube after treatment. A 77-year-old man presented with sudden loosening of his PEG tube with a duration over 3 days. He had undergone PEG procedure three times until that time. During workup, a gastrocolocutaneous fistula was diagnosed. However, when previous studies were reviewed, an abdominal CT scan, which was done 6 months ago before the third PEG, showed the fistula already existed at that time, suggesting that it was created about 33 months earlier when he underwent the second PEG procedure. The patient died of pneumonia aggravation despite conservative treatment. Both a high index of suspicion and the careful inspection of the upper endoscopy are very important for early diagnosis regardless of symptoms.
Aged ; Colon, Transverse ; Diarrhea ; Early Diagnosis ; Endoscopy ; Fistula* ; Gastrostomy* ; Humans ; Pneumonia ; Tomography, X-Ray Computed
Aged ; Colon, Transverse ; Diarrhea ; Early Diagnosis ; Endoscopy ; Fistula* ; Gastrostomy* ; Humans ; Pneumonia ; Tomography, X-Ray Computed
The Prognostic Significance of Fascin Expression in Colorectal Carcinoma.
Intestinal Research.2010;8(2):117-125. doi:10.5217/ir.2010.8.2.117
BACKGROUND/AIMS: Fascin, an actin-bundling protein found in membrane ruffles, microspikes, and stress fibers, induces membrane protrusions and increases cell motility in normal and various transformed cells. The expression of fascin in epithelial neoplasms has only been described recently, and the role of fascin in colorectal carcinoma (CRC) is still unknown. METHODS: Paraffin sections of CRC from 79 patients were immunohistochemically investigated using monoclonal anti-fascin antibody. Staining of >5% of tumor cells was recorded as positive immunoreactivity. RESULTS: Overall, fascin immunoreactivity was detected in 63 of 79 patients (79.7%). Twenty-three patients were classified as 1+ (5-25% immunoreactive tumor cells) and 24 were 2+ (>25% immunoreactive tumor cells). In these patients, 16 had 3+ (>75% immunoreactive tumor cells) fascin immunoreactivity. Fascin immunoreactivity was increased according to the TNM stage (P<0.001), positive lymph node metastasis (P<0.001), budding (P<0.001), vessel invasion (P=0.001), perineural invasion (P=0.039), overall survival (P=0.012), and disease-free survival (P=0.016); however, fascin immunoreactivity was not correlated with recurrence or depth of tumor invasion. CONCLUSIONS: This study suggests that an increased expression of fascin was associated with a poor prognosis and the immunohistochemical detection of fascin provides useful information as one of the prognostic values in CRC.
Carrier Proteins ; Cell Movement ; Colorectal Neoplasms ; Disease-Free Survival ; Glycosaminoglycans ; Humans ; Immunohistochemistry ; Lymph Nodes ; Membranes ; Microfilament Proteins ; Neoplasm Metastasis ; Neoplasms, Glandular and Epithelial ; Paraffin ; Prognosis ; Recurrence ; Stress Fibers
Carrier Proteins ; Cell Movement ; Colorectal Neoplasms ; Disease-Free Survival ; Glycosaminoglycans ; Humans ; Immunohistochemistry ; Lymph Nodes ; Membranes ; Microfilament Proteins ; Neoplasm Metastasis ; Neoplasms, Glandular and Epithelial ; Paraffin ; Prognosis ; Recurrence ; Stress Fibers
Small Intestinal Bacterial Overgrowth.
Intestinal Research.2010;8(2):106-116. doi:10.5217/ir.2010.8.2.106
Small intestinal bacterial overgrowth (SIBO) syndrome is characterized by an imbalance of a complex microbiome in the gut. The underlying factors include anatomic abnormalities, (small intestinal obstruction, diverticular disease, fistulas, blind or afferent loops, and previous ileo-cecal resection), motility disorders (scleroderma, diabetic autonomic neuropathy, and ileus), and some conditions associated with failure of antibacterial defense mechanisms (achlorhydria, pancreatic exocrine insufficiency, and an immunosuppressed state). In recent studies, there is abundant evidence suggesting the relationship between SIBO and irritable bowel syndrome; however, it is not clear which disease is a primary factor to the other. Symptoms related to SIBO include diarrhea, bloating, malabsorption, weight loss, and anemia. The gold standard test for the diagnosis of SIBO is aspiration of jejunal fluid for culture. However, non-invasive hydrogen and methane breath tests are more widely used for the diagnosis, although they have several potential problems affecting the diagnostic accuracy. The treatment should be individualized, and usually consists of correction of the underlying predisposing disease, nutritional support, and cyclic or repeated courses of antimicrobials.
Anemia ; Breath Tests ; Defense Mechanisms ; Diabetic Neuropathies ; Diarrhea ; Fistula ; Hydrogen ; Intestinal Obstruction ; Metagenome ; Methane ; Nutritional Support ; Weight Loss
Anemia ; Breath Tests ; Defense Mechanisms ; Diabetic Neuropathies ; Diarrhea ; Fistula ; Hydrogen ; Intestinal Obstruction ; Metagenome ; Methane ; Nutritional Support ; Weight Loss
Irritable Bowel Syndrome in Inflammatory Bowel Disease.
Intestinal Research.2010;8(2):95-105. doi:10.5217/ir.2010.8.2.95
Clinicians are frequently challenged to interpret gastrointestinal symptoms in patients with inflammatory disease (IBD). Irritable bowel syndrome (IBS)-like symptoms are common in patients with IBD and the underlying mechanism is likely to be active or occult inflammation of the bowel rather than co-existing IBS. Biopsychosocial construct and mucosal inflammation, stress, alteration of the hypothalamic-pituitary-adrenal axis, and autonomic dysregulation are contributing factors to IBD-IBS. In particular, low-grade inflammation and immune activation are recent topics regarding the underlying mechanism. Some authors have claimed that inflammation could be a common pathophysiologic factor, in which IBS and IBD might represent the two ends of a wide spectrum of chronic inflammatory conditions. Mast cells, enteroendocrine cells, T cells, and B cells are main effector cells in immune responses. Differentiating IBS symptoms from exacerbation of IBD is important, thus preventing the use of excessive IBD medications, with the potential side effects, or narcotics. Medical treatments with anti-diarrheals, anti-spasmodics, anti-depressants, and anxiolytics can be helpful. However, abuse can lead to medication-dependency and bring about side effects. A healthy, balanced lifestyle, including diet and exercise, should be endorsed.
Anti-Anxiety Agents ; Axis, Cervical Vertebra ; B-Lymphocytes ; Colitis, Microscopic ; Diet ; Enteroendocrine Cells ; Humans ; Immunity, Mucosal ; Inflammation ; Inflammatory Bowel Diseases ; Irritable Bowel Syndrome ; Life Style ; Mast Cells ; Narcotics ; T-Lymphocytes
Anti-Anxiety Agents ; Axis, Cervical Vertebra ; B-Lymphocytes ; Colitis, Microscopic ; Diet ; Enteroendocrine Cells ; Humans ; Immunity, Mucosal ; Inflammation ; Inflammatory Bowel Diseases ; Irritable Bowel Syndrome ; Life Style ; Mast Cells ; Narcotics ; T-Lymphocytes
Country
Republic of Korea
Publisher
Korean Association for the Study of Intestinal Diseases
ElectronicLinks
http://synapse.koreamed.org/LinkX.php?code=0143IREditor-in-chief
You Sun Kim
thekasid@irjournal.org
Abbreviation
Intest Res
Vernacular Journal Title
ISSN
1598-9100
EISSN
2288-1956
Year Approved
2008
Current Indexing Status
Currently Indexed
Start Year
Description
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include colon and small intestine cancer or polyp, inflammatory bowel disease, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth.
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)